CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

COVID-19: An overview of current scenario

  • Received : 2020.05.20
  • Accepted : 2020.06.11
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Over a span of few decades, the world has seen the emergence of new viruses that have posed serious problems to global health .COVID-19 is a major pathogenic threat to the modern world that primarily shoots the respiratory system of human beings. Wuhan which is the capital city of Hubei, China was the first place in the world where first cases of COVID-19 emerged and the scores of cases significantly increased at an immense rate leading to city isolation and establishment of new specially designed hospitals. SARS-CoV had emerged from bats in china (2002) and MERS-CoV from camels transmitted via bats in Middle East (2012) where the previous versions of COVID-19 took place. Infections with SARS-CoV-2 are now widespread, like Nuclear Chain Reaction (NRC). In this review we will discuss the COVID-19 origin, transmission, incubation, diagnosis and therapies available at the present scenario.

Keywords

References

  1. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3): 313-324. https://doi.org/10.4014/jmb.2003.03011
  2. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA.Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. International Journal of Infectious Diseases. 2014;20: 42-46. https://doi.org/10.1016/j.ijid.2013.12.003
  3. Anderson G, Maes M, Markus RP, Rodriguez M. Ebola virus: melatonin as a readily available treatment option. Journal of medical virology. 2015;87(4): 537-543. https://doi.org/10.1002/jmv.24130
  4. Andre FE. The future of vaccines, immunisation concepts and practice. Vaccine. 2001;19(17-19): 2206-2209. https://doi.org/10.1016/S0264-410X(00)00546-6
  5. Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerging infectious diseases. 2013; 19(3): 456. https://doi.org/10.3201/eid1903.121503
  6. Anonymous. WORLDOMETERS, YNM, Available at: https://www.worldometers.info/coronavirus/
  7. Backer J, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among travellers from Wuhan. China. medRxiv. 2020(27.20018986).
  8. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Eurosurveillance. 2020;25(5): 2000062.
  9. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020; 323(14): 1406-1407. https://doi.org/10.1001/jama.2020.2565
  10. Ben-Nathan D, Maestroni G, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Archives of virology. 1995;140(2): 223-230. https://doi.org/10.1007/BF01309858
  11. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this "molecular handyman"? Reviews in medical virology. 2012;22(5): 323-338. https://doi.org/10.1002/rmv.1714
  12. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223): 514-523. https://doi.org/10.1016/S0140-6736(20)30154-9
  13. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet infectious diseases. 2020a;20(4): 398-400. https://doi.org/10.1016/S1473-3099(20)30141-9
  14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020b;395(10223): 507-513. https://doi.org/10.1016/s0140-6736(20)30211-7
  15. Chen Y, Chan K-H, Kang Y, Chen H, Luk HK, Poon RW, et al. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerging microbes & infections. 2015;4(1): 1-5.
  16. Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. (2005). Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(1): 44-46. https://doi.org/10.1007/s10096-004-1271-9
  17. Choy M. Pharmaceutical approval update. Pharmacy and Therapeutics. 2016; 41(5): 288.
  18. Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3): 252-256. https://doi.org/10.1136/thorax.2003.012658
  19. Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. Journal of virology. 2014; 88(19): 11297-11303. https://doi.org/10.1128/JVI.01498-14
  20. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3): 1560-7917.
  21. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah N, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral research. 2020; 176: 104742. https://doi.org/10.1016/j.antiviral.2020.104742
  22. da Cunha Pedrosa AM, Weinlich R, Mognol GP, Robbs BK, de Biaso Viola JP, Campa A, et al. Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation. The Journal of Immunology. 2010; 184(7): 3487-3494. https://doi.org/10.4049/jimmunol.0902961
  23. De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry-An Asian Journal. 2019; 14(22): 3962-3968. https://doi.org/10.1002/asia.201900841
  24. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58(1): 267-273. https://doi.org/10.1128/AAC.01795-13
  25. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020; 117(17): 9490-9496. https://doi.org/10.1073/pnas.2004168117
  26. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015;1-23
  27. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annual review of microbiology. 2019; 73: 529-557. https://doi.org/10.1146/annurev-micro-020518-115759
  28. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1): 72-73. https://doi.org/10.5582/bst.2020.01047
  29. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature Reviews Microbiology. 2013; 11(12): 836-848. https://doi.org/10.1038/nrmicro3143
  30. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv, 2020.
  31. Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Am J Clin Pathol. 2020; 153(4): 420-421. https://doi.org/10.1093/ajcp/aqaa029
  32. Hardeland R. Melatonin and inflammation-Story of a double-edged blade. Journal of pineal research. 2018; 65(4): e12525. https://doi.org/10.1111/jpi.12525
  33. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochemical and biophysical research communications. 2004; 324(2): 773-781. https://doi.org/10.1016/j.bbrc.2004.09.106
  34. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine, 2020.
  35. Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017; 123(17): 3326-3334. https://doi.org/10.1002/cncr.30739
  36. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
  37. Huang SH, Cao XJ, Liu W, Shi XY, Wei W. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. Journal of pineal research. 2010; 48(2): 109-116. https://doi.org/10.1111/j.1600-079X.2009.00733.x
  38. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases. 2011; 52(4): 447-456. https://doi.org/10.1093/cid/ciq106
  39. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. Journal of virology. 2012; 86(23): 12816-12825. https://doi.org/10.1128/JVI.00906-12
  40. Junaid A, Tang H, van Reeuwijk A, Abouleila Y, Wuelfroth P, van Duinen V, et al. Ebola Hemorrhagic Shock Syndrome-on-a-Chip. iScience. 2020; 23(1): 100765. https://doi.org/10.1016/j.isci.2019.100765
  41. Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. Journal of virology. 2005; 79(18): 11892-11900. https://doi.org/10.1128/JVI.79.18.11892-11900.2005
  42. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and biophysical research communications. 2004; 323(1): 264-268. https://doi.org/10.1016/j.bbrc.2004.08.085
  43. Ko J-H, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral therapy. 2018; 23(7): 617-622. https://doi.org/10.3851/IMP3243
  44. Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral research. 2008; 77(2): 150-152. https://doi.org/10.1016/j.antiviral.2007.10.011
  45. Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, et al. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. Journal of virology. 2013; 87(15): 8638-8650. https://doi.org/10.1128/JVI.01055-13
  46. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. Journal of Microbiology, Immunology and Infection, 2020.
  47. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020; 295(1): 31.
  48. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. The Lancet infectious diseases. 2009; 9(5): 291-300. https://doi.org/10.1016/S1473-3099(09)70069-6
  49. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Journal of virology. 2005; 79(3): 1943-1947. https://doi.org/10.1128/JVI.79.3.1943-1947.2005
  50. Li F. Structure, function, and evolution of coronavirus spike proteins. Annual review of virology. 2016; 3: 237-261. https://doi.org/10.1146/annurev-virology-110615-042301
  51. Li J, Zhang C, Shan H. Advances in mRNA vaccines for infectious diseases. Frontiers in Immunology. 2019; 10: 594. https://doi.org/10.3389/fimmu.2019.00594
  52. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020b; 382(13): 1199-1207. https://doi.org/10.1056/NEJMoa2001316
  53. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310(5748): 676-679. https://doi.org/10.1126/science.1118391
  54. Ling Y, Li ZZ, Zhang JF, Zheng XW, Lei ZQ, Chen RY, et al. MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome. Life sciences. 2018; 210: 1-8. https://doi.org/10.1016/j.lfs.2018.08.037
  55. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-m, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. Journal of clinical medicine. 2020; 9(2): 538. https://doi.org/10.3390/jcm9020538
  56. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese medical journal, 2020.
  57. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020; 395(10224): 565-574. https://doi.org/10.1016/S0140-6736(20)30251-8
  58. Mahase E. China coronavirus: WHO declares international emergency as death toll exceeds 200. Bmj. 2020; 368: m408. https://doi.org/10.1136/bmj.m408
  59. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases. 2015; 211(1): 80-90. https://doi.org/10.1093/infdis/jiu396
  60. Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Veterinary quarterly. 2020; 40(1): 68-76. https://doi.org/10.1080/01652176.2020.1727993
  61. Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. Journal of Dental Research. 2020; 99(5): 481-487. https://doi.org/10.1177/0022034520914246
  62. Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus research. 2014; 194: 175-183. https://doi.org/10.1016/j.virusres.2014.03.018
  63. Mukherjee P, Desai P, Ross L, White EL, Avery MA. Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits. Bioorganic & medicinal chemistry.2008; 16(7): 4138-4149. https://doi.org/10.1016/j.bmc.2008.01.011
  64. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PloS one. 2013; 8(3).
  65. Que T, Wong V, Yuen K. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6): 399-406.
  66. Reiter RJ, Ma Q, Sharma R. Melatonin in mitochondria: mitigating clear and present dangers. Physiology. 2020a; 35(2): 86-95. https://doi.org/10.1152/physiol.00034.2019
  67. Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin "goes viral". Melatonin Research. 2020b; 3(1): 43-57. https://doi.org/10.32794/mr11250047
  68. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109(102433): 26.
  69. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England Journal of Medicine. 2020; 382(10): 970-971. https://doi.org/10.1056/NEJMc2001468
  70. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases. 2003; 3(11): 722-727. https://doi.org/10.1016/S1473-3099(03)00806-5
  71. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A New insights into the antiviral effects of chloroquine. edn. The Lancet Infect Dis. 2006; 6(2):67-9. https://doi.org/10.1016/S1473-3099(06)70361-9
  72. Shang Y, Xu SP, Wu Y, Jiang Y, Wu ZY, Yuan S, et al. Melatonin reduces acute lung injury in endotoxemic rats. Chinese medical journal. 2009; 122(12): 1388-1393. https://doi.org/10.3760/cma.j.issn.0366-6999.2009.12.006
  73. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine.2017; 9(396).
  74. Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus research. 2008; 133(1): 74-87. https://doi.org/10.1016/j.virusres.2007.03.012
  75. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020; 87(4): 281-286. https://doi.org/10.1007/s12098-020-03263-6
  76. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. The Lancet. 2003; 361(9369): 1615-1617. https://doi.org/10.1016/S0140-6736(03)13265-5
  77. Sola I, Almazan F, Zuniga S, Enjuanes L. Continuous and discontinuous RNA synthesis in coronaviruses. Annual review of virology. 2015; 2: 265-288. https://doi.org/10.1146/annurev-virology-100114-055218
  78. Sun CK, Lee FY, Kao YH, Chiang HJ, Sung PH, Tsai TH, et al. Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. Journal of pineal research. 2015; 58(2): 137-150. https://doi.org/10.1111/jpi.12199
  79. Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. New England Journal of Medicine. 2016; 374(1): 33-42. https://doi.org/10.1056/NEJMoa1511812
  80. Varia M, Wilson S, Sarwal S, McGeer A, Gournis E, Galanis E. Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. Cmaj. 2003; 169(4): 285-292.
  81. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005; 2(1): 69. https://doi.org/10.1186/1743-422X-2-69
  82. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020a; 395(10223): 470-473. https://doi.org/10.1016/S0140-6736(20)30185-9
  83. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020b; 323(11): 1061-1069. https://doi.org/10.1001/jama.2020.1585
  84. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020c; 30(3): 269-271. https://doi.org/10.1038/s41422-020-0282-0
  85. Wang Q-L, Yang L, Peng Y, Gao M, Yang M-S, Xing W, et al. Ginsenoside Rg1 regulates SIRT1 to ameliorate sepsis-induced lung inflammation and injury via inhibiting endoplasmic reticulum stress and inflammation. Mediators of inflammation. 2019.
  86. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. Journal of medical virology.2020d; 92(4): 441-447.
  87. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. (2016). Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication. Antimicrobial agents and chemotherapy. 2016; 60(5):2834-2848. https://doi.org/10.1128/AAC.02700-15
  88. Wu C-Y, Jan J-T, Ma S-H, Kuo C-J, Juan H-F, Cheng Y-SE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proceedings of the National Academy of Sciences. 2004; 101(27):10012-10017. https://doi.org/10.1073/pnas.0403596101
  89. Wu X, Ji H, Wang Y, Gu C, Gu W, Hu L, et al. Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 Axis. Oxidative medicine and cellular longevity. 2019.
  90. Yan Y, Zou Z, Sun Y, Li X, Xu K-F, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell research. 2013; 23(2):300-302. https://doi.org/10.1038/cr.2012.165
  91. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxiv, 2020.
  92. Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, et al. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. Journal of pineal research. 2013; 54(2): 207-221. https://doi.org/10.1111/jpi.12020
  93. Zheng BJ, Guan Y, Wong KH, Zhou J, Wong KL, Young BWY, et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerging infectious diseases. 2004; 10(2):176. https://doi.org/10.3201/eid1002.030533
  94. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. New England Journal of Medicine. 2007; 357(14):1450-1451. https://doi.org/10.1056/NEJMc070359
  95. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. https://doi.org/10.1056/NEJMoa2001017
  96. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nature reviews Drug discovery. 2016; 15(5):327. https://doi.org/10.1038/nrd.2015.37